To Lucy 4

What Happened Lucy, the Chief Financial Officer of SAB Biotherapeutics (SABS), received a grant of derivative awards on February 3, 2026: options covering 2,400,000 shares (reported at $0.00 per share in the filing). This was an equity award (transaction code A), not an open‑market purchase or sale — the grant gives the right to acquire common stock subject to vesting and any future exercise requirements.

Key Details

• Transaction date: 2026-02-03; Form 4 filed 2026-02-05 (appears timely).
• Award: Options to purchase 2,400,000 shares (reported acquisition price $0.00; classified as a derivative).
• Vesting: 4-year schedule — 1/4 vests on the one‑year anniversary, then the remaining 3/4 vests in 36 monthly installments (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: Grant made under the Issuer’s 2021 Omnibus Equity Incentive Plan.

Context This is a standard executive equity award used for compensation and retention. The options do not represent immediately tradable shares — they vest over time and typically require exercise (and possibly payment of an exercise price not disclosed here) before the insider would hold or sell common stock. No immediate sale or exercise was reported in this filing.